Man Group
CHRS icon

Man Group’s Coherus Oncology CHRS Stock Holding History

Man Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,685
Closed -$283K – 2099
2022
Q4 		$283K Buy
+35,685
New +$275K ﹤0.01% 1666
2020
Q4 		– Sell
-89,993
Closed -$1.65M – 1830
2020
Q3 		$1.65M Buy
89,993
+20,910
+30% +$389K 0.01% 1249
2020
Q2 		$1.23M Buy
69,083
+51,683
+297% +$875K 0.01% 1213
2020
Q1 		$282K Buy
+17,400
New +$321K ﹤0.01% 1396

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Man Group's CHRS Position: Q1 2023 in Review

Man Group sold out of Coherus Oncology (CHRS) in Q1 2023, closing a stake of 35,685 shares — an estimated $283K sold.

Man Group first reported a position in CHRS in Q1 2020 and held it in 4 quarters. The position peaked at $1.65M in Q3 2020. 163 funds tracked by Wall St. Rank hold CHRS as of Q1 2023.

  • Man Group reported no remaining Coherus Oncology position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 35,685 Coherus Oncology shares in Q1 2023, an estimated $283K.
  • Man Group first reported a position in Coherus Oncology in Q1 2020 and held it in 4 quarters.
  • Man Group's Coherus Oncology position peaked at $1.65M in Q3 2020.
  • 163 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.